Objectives: Change in 18 F-FDG uptake may predict response to anticancer treatment.
INTRODUCTION
18 F-fluorodeoxyglucose ( 18 F-FDG) is widely used as a diagnostic or prognostic tool in oncology, but its role as biomarker of response to cancer therapy is less well established (1-5). Evaluation of response using positrion emmison tomography (PET) can be performed visually (e.g. International Conference on Malignant Lymphoma taxonomy in malignant lymphoma (6) ) or (semi)quantitatively (2) . For the latter, the proposed PET Response Criteria in Solid Tumors (PERCIST) suggest a threshold of 30% change in standardized uptake value (SUV) (combined with a minimal absolute change) to define either partial response or progressive disease (3) . Evidence underlying these thresholds consists of mixed test-retest data from stand-alone PET and PET/CT scanners, with variable uptake intervals (3, 7) . To date, optimal tracer uptake time for response assessment is still matter of debate (60 vs. 90 min post-injection).
Furthermore, traditionally most repeatability studies reported on solitary tumor measurements (7) . Yet, thresholds for response evaluation should also apply to patients with multiple metastases. The PERCIST suggest measuring up to 5 lesions for response assessment; however the impact of lesion selection strategies on repeatability requires further research.
More recently, two PET/CT studies performed in ovarian and non-small cell lung cancer (NSCLC) patients showed conflicting results on repeatability of SUV measurements (8, 9) . As discussed, only SUV metrics were assessed in these studies and the effect of normalization to blood or liver SUV has not been evaluated. This, however, could improve repeatability of the uptake metrics (10, 11) . Finally, there is an increasing interest in alternative 18 F-FDG uptake measures, such as total lesion glycolysis (TLG) and metabolically active tumor volume (MATV) (3, 12) . There are only limited data on the test-retest performance of these uptake metrics and influence of uptake time interval and lesion selection have not been investigated to our knowledge.
The aim of this study was therefore to comprehensively investigate the repeatability of various quantitative whole-body 18 F-FDG uptake and volumetric measures in advanced NSCLC patients as a function of tracer uptake interval and lesion selection strategy. Furthermore, we evaluated two proposed methods to account for variable uptake intervals.
MATERIALS AND METHODS

Patients
11 NSCLC patients (7 men) with at least one intra-thoracic lesion ≥ 3cm in the largest diameter, who had not received chemotherapy in the past 4 weeks and without known diabetes mellitus, were included between January 2013 and January 2015 by their pulmonary physician in the VU University Medical Center, Amsterdam, The Netherlands. Patients underwent double baseline whole body 18 F-FDG PET/CT scans at 60 and 90 minutes post-injection (p.i.). In total, 11 and 10 test-retest scans were obtained at 60 and 90 minutes p.i. respectively (one patient did not undergo one 90 minutes scan due to back pain). There were no significant differences in patient preparation and PET acquisition between the test and retest scans (Table 4 .1). This study was approved by the institutional review board and was registered in the Dutch trial register (trialregister.nl, NTR3508). Written informed consent for all subjects was obtained prior to study enrolment.
PET Imaging
All PET scans were obtained using a Philips Gemini TF PET/CT scanner (Philips Healthcare, Eindhoven, The Netherlands). Scans were obtained and reconstructed following the guideline recommendations of the European Association of Nuclear Medicine (13) . Patients were asked to fast at least 6 hours before the PET scan, and blood glucose levels were measured twice before tracer injection to correct for measurement errors. Patients underwent a low-dose CT during tidal breathing for attenuation correction, followed by a whole body 18 F-FDG PET/CT scan (skull vertex to mid-thigh) 60 min p.i. at 2 minutes per bed position. Ninety minutes p.i. a second whole body PET scan was acquired, followed by a second low-dose CT for attenuation correction. This procedure was repeated within 3 days after the first scan. Weight, height, total injected activity, time of injection, residual activity and exact scan start time of both time points were recorded for each session. 
Data Analysis
Volumes of interest (VOIs) were generated by delineating 18 F-FDG avid tumors using a 50% threshold of SUVpeak adapted for local background (in-house developed software). Details on this method were published previously (12) . Tumors were selected by a nuclear physician. For each VOI, SUVmax (maximum SUV), SUVmean (mean SUV), SUVpeak (1.2cm 3 spheric region positioned to maximize its mean value), MATV (50% threshold of SUVpeak corrected for local background), TLG (product of SUVmean and MATV), and tumor-to-blood and tumor-to-liver ratios were determined. The SUVmean of a VOI placed in the ascending aorta (3.3 mL) and liver (14 mL) were used for normalization to blood and liver uptake. SUVs were corrected for lean body mass using James formula (13) and all uptake measures were assessed with and without glucose correction.
We applied two methods for correction of uptake metrics for uptake time differences as described by van den Hoff et al. (14) . The first corrects the 90 minutes data to 60 minutes by estimating the 60 minutes SUVs using
Here SUR represents the tumor-to-blood uptake value and VR the apparent volume of distribution, which was set to 0.53 and the time exponent b was set to 0.313 according to van den Hoff et al. We also determined exponent b for our study population using the group-averaged blood activity resulting in a b value of 0.5. The second method to correct SUV for uptake time is based on the rule of thumb that SUR0/SURT ≈ (T0/T) resulting in:
Statistical Analysis
We determined repeatability by calculating the mean and standard deviation (SD) of the absolute and percentage differences between the test and retest scan.
Percentage difference was calculated as:
The reproducibility coefficient (RC) was calculated as 1.96 x SD of the percentage and absolute differences for all uptake metrics at both time points.
Normality was assessed using a quantile-quantile plot and histogram analyses. A paired t test was used to test for significant differences in mean uptake between the test and retest scan and the Levene's test was performed to investigate whether differences in RC were significant. Additionally, linear regression analyses, intraclass correlation coefficient (ICC), and Bland-Altman plots were used to evaluate repeatability.
Repeatability of SUV metrics, MATV, and TLG were evaluated as function of uptake interval, glucose correction and normalisation procedures for SUV metrics 
RESULTS
Repeatability of Uptake Metrics
Test-retest variability was analysed in 9 NSCLC patients (stage IV) with a total of 60 lesions (Table 4 .1). Two patients were excluded from the analysis, one because no retest scan at 90 minutes was obtained and the second due to movement during the retest scan at 60 minutes (mean difference for all uptake measures > 2 SDs). Data including the latter patient are shown in the supplemental section. equalled the averaged PERCIST data and were not influenced by the outlier. Test-retest variability obtained for lung lesions and lesions > 4.2 mL was similar to those of PERCIST target lesions. Moreover, both intra-and extrathoracic lesions were included and no differences in repeatability were found depending on tumor location.
Normalisation to Blood or Liver Uptake and Glucose Correction
Hepatic 18 F-FDG uptake was independent of uptake interval and showed low inter-scan variability between the test and retest scans (median: 0.01; IQR: 0.09).
Normalisation of SUV to liver uptake did not affect repeatability for any of the uptake measures and times. Normalisation to blood uptake did not influence repeatability for the 60 minutes uptake time, but in the 90 minutes data RCs increased from 17.1% ± 4.0% to 29.6% ± 3.0%. Furthermore, plasma glucose correction adversely affected repeatability at both time points. minutes data for all uptake measures. The 90 minutes data estimated to 60 minutes using equation 2 correlated better with the 60 minutes data than those using the ruleof-thumb (eq. 3). However, mean differences remained more than 5% and were significant. After the b value was adjusted to 0.5, correlation further improved and the estimated values no longer differed from the 60 minutes SUVmean and SUVpeak data regardless of the lesions included (Figure 4.4) . RCs of the percentage difference between the 60 minutes data and the 90 minutes data corrected to 60 minutes were similar to those of corresponding uptake metrics described above.
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DISCUSSION
In this study, repeatability of SUV metrics was superior to TLG and MATV and after PERCIST lesion selection criteria were applied RCs improved to < 15%. We observed similar repeatability performance characteristics of several quantitative 18 A recent multi-center study evaluated 18 F-FDG PET/CT in 74 NSCLC patients accrued at 24 different sites (9) . In contrast to the former studies, here a threshold of 28% decrease and 39% increase for SUVmax (32% decrease and 47% increase for SUVpeak) were found to reflect true therapeutic effects if per patient only one lesion > 2 cm, with the highest SUVmax (> 4 g/mL) was included. These results are comparable to those shown in a multi-center study performed by Velasquez et al. (16) , suggesting that repeatability of 18 F-FDG PET might be more limited in a multi-center setting. In this current study, we performed 18 F-FDG PET/CT scans very strictly, this might be more difficult in multi-center setting and could result in an accumulation of small errors which could affect test-retest performance. Additionally differences in VOI definition of SUVpeak in our study versus those published elsewhere could partly explain reported differences in repeatability (17) . In contrast to our study, in which we positioned a 1.2 cm 3 spheric VOI within tumor borders defined by a 50% isocontour to obtain the highest peak value, Weber et al. (9) placed a 1.5 cm diameter cylindric VOI in three consecutive axial slices over the voxel with the maximum uptake and the report did not specify whether a tumor border was defined. Therefore, there is a risk that nonmalignant tissue is taken into account when the maximum voxel is located near the edge of the tumor, and repeatability could be seriously affected by the variable location
of the maximum voxel, which is susceptible to noise (18, 19) . Furthermore, they assessed differences between test and retest scans after averaging all lesions in individual patients, because this may have a better correlation with patient outcome (9) . Contrary to our results, no improvement in repeatability was found. Yet, improvement of variability would be expected if no systematic difference between both baseline scans exists, since differences would be reduced by averaging the data. Change in MATV has been shown to predict pathologic response in breast cancer after 2 cycles of chemotherapy, but few studies have assessed the repeatability of this parameter (20) (21) (22) . The repeatability of MATV was better in our study than in studies published by Frings et al. (22) in NSCLC patients and Hatt et al. (20) in esophageal cancer patients. These discrepancies are most likely explained by differences in uptake time (45 vs. 60 minutes p.i.) and VOI definition respectively. TLG has properties similar to MATV and showed similar repeatability, yet was influenced by uptake time. Two other studies investigated TLG repeatability in liver metastases and found RCs of 31.2% (23, 24) . The differences may partly be explained by differences in tumor type, as liver metastases tend to be more irregular compared to lung lesions and repeatability could be affected by higher background activity of the liver. Moreover, VOIs were delineated using a 41% (24) and 50% (23) isocontour corrected for local background based on SUVmax which could influence repeatability. Whether changes in FDG uptake metrics beyond the repeatability confidence intervals presented here also reflect sufficient clinical response remains to be shown.
Normalisation to Blood or Liver Uptake and Glucose Correction
Glucose correction deteriorated the test-retest performance in our study. Serum glucose levels were all within reference range and showed limited variability between the test and retest scan (< 2.2 mmol/L). Including this additional variable in the calculation of 18 F-FDG uptake metrics increases uncertainty and suggests that glucose correction should not be used when glucose levels are within reference range.
Furthermore, we normalized SUV measures to liver and blood uptake to correct for inaccuracies in dose calibration, weight and length measurements and variations of tracer supply to the tumor (3, 25) . There was only little variability in the liver uptake between scans (1 ± 4%) yielding no improvement of repeatability. The same applies for the tumor-to-blood ratios in the 60 minutes data in contrast to expectations of van den Hoff et al. (10) . Moreover, normalization to blood increased variability in the 90 minutes data, which might be explained by low count statistics (higher sensitivity to noise) of blood SUV at 90 minutes p.i..
Uptake Time Correction
Variation in uptake time has an important impact on the use of 18 
. This discrepancy might be explained by differences in patient preparation (e.g.
longer fasting prior to the scan or better prehydration and therefore more excretion).
Moreover, in our study patients were scanned at two separate days and could therefore be affected by physiologic differences, but this has to be further explored. Despite the need for (minor) adjustment of one of the parameters of the uptake time correction method, we found a good correspondence between 90 and 60 min p.i. uptake metrics without affecting repeatability and therefore we propose further evaluation as a potential strategy to compensate for unwanted variability in uptake times during longitudinal studies.
Limitations
The main limitation to this study is the relatively small sample size.
Unfortunately patient burden due to long scan time (± 60 minutes), because of the 60 and 90 minutes acquisitions, limited the collection of large datasets. However, to our knowledge no other studies have assessed these issues in such a comprehensive study design. Ideally, large multicentre trials should confirm our results, but implementation of this protocol into a trial would significantly increase the patient burden and would be less feasible compared with a repeatability study at one time-point only.
Second, we only assessed NSCLC patients, possibly limiting extrapolation to other tumor types. However, also extrathoracic lesions were included and there were no differences in repeatability depending on tumor location.
CONCLUSIONS
The results of this prospective study suggest that if up to 5 PERCIST target lesions are included, a 15% change of SUVmean or SUVpeak reflects true metabolic response in patients with advanced NSCLC. If response is assessed using the averaged PERCIST target lesions this threshold could even be set at a < 10% change. No differences in test-retest performances were observed at 60 and 90 minutes postinjection and normalization to blood or liver uptake did not improve repeatability.
Whether the thresholds found in this study are also valid in well-controlled multicenter studies, remains to be shown. 
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